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Inflammation is recognized as an important contributor
to lymphangiogenesis; however, in tubulointerstitial lesions
in human chronic kidney diseases, this process is better
correlated with the presence of myofibroblasts rather than
macrophages. As little is known about the interaction between
lymphangiogenesis and renal fibrosis, we utilized the rat
unilateral ureteral obstruction model to analyze inflammation,
fibrosis, lymphangiogenesis, and growth factor expression.
Additionally, we determined the relationship between vascular
endothelial growth factor-C (VEGF-C), an inducer of lymphan-
giogenesis, and the profibrotic factor, transforming growth
factor-b1 (TGF-b1). The expression of both TGF-b1 and VEGF-
C was detected in tubular epithelial and mononuclear cells,
and gradually increased, peaking 14 days after ureteral
obstruction. The kinetics and localization of VEGF-C were
similar to those of TGF-b1, and the expression of these
growth factors and lymphangiogenesis were linked with the
progression of fibrosis. VEGF-C expression was upregulated
by TGF-b1 in cultured proximal tubular epithelial cells, col-
lecting duct cells, and macrophages. Both in vitro and in vivo,
the induction of VEGF-C along with the overall appearance of
lymphatics in vivo was specifically suppressed by the TGF-b
type I receptor inhibitor LY364947. Thus, TGF-b1 induces
VEGF-C expression, which leads to lymphangiogenesis.
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Blood vessels have a continuous basal lamina with tight
inter-endothelial junctions and are supported by pericytes
and smooth muscle cells. In contrast, lymphatic endo-
thelial cells have a thin discontinuous basement membrane
and have gaps between the cells that open to the adjacent
connective tissues.1 In edematous tissue, the lymphatic
endothelial cells are pulled by anchoring filaments and
bileaflet valves to prevent the backflow of lymphatic fluid.2
These structures remove tissue fluid from the inter-
stitium and transfer extravasated plasma protein and cells
back into circulation. In this respect, lymphatic vessels
are essential for body fluid balance and immunological
surveillance.3
Increases in lymphatic vessels have recently been reported
in several disease conditions, including tumor metastasis,4–7
chronic respiratory inflammatory diseases,8 wound healing,9
renal transplant rejection,10,11 and granulation tissues in
myocardial infarction.12 Inflammation is recognized as an
important contributor to lymphangiogenesis in human
diseases10,13 and in animal models.14,15 In particular, macro-
phages are involved in lymphangiogenesis in the production
of vascular endothelial growth factor (VEGF)-C and -D,
which are recognized as potentially important mediators for
lymphangiogenesis.16 Interleukin-1b and tumor necrosis
factor-a have been shown to induce the upregulation of
VEGF-C.17 In addition, CD11bþ macrophages may form
lymphatic-like vessels in vitro.14,18 A recent report showed
that inflammation induced lymphangiogenesis through the
upregulation of VEGF receptor-3 mediated by nuclear factor-
kappa-B and prospero-related homeobox 1.19
In chronic kidney disease, we recently reported an increase
in the number of lymphatics observed at the site of tubulo-
interstitial lesions and this increase was correlated with
http://www.kidney-international.org o r ig ina l a r t i c l e
& 2012 International Society of Nephrology
Received 11 January 2011; revised 5 October 2011; accepted 1
November 2011; published online 18 January 2012
Correspondence: Yasuhiko Ito, Department of Nephrology, Nagoya
University, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan.
E-mail: yasuito@med.nagoya-u.ac.jp
Kidney International (2012) 81, 865–879 865
degree of tissue damage. In addition, lymphangiogenesis was
more strongly correlated with fibrosis than inflammation
on analysis of human glomerular diseases and acute and
chronic tubulo-interstitial nephritis.20 We also demonstrated
strong expression of VEGF-C in the proximal tubules.20 Our
results indicated that lymphangiogenesis is a common feature
in the progression of tubulo-interstitial fibrosis, and the
fibrotic process may play a role in the development of
lymphatics.20 However, there has been little focus on the role
of transforming growth factor (TGF)-b, one of the most
important mediators for tissue fibrosis, in lymphangiogenesis
to date.
In this study, we investigated the roles of TGF-b and
VEGF-C in the development of lymphangiogenesis in the
unilateral ureteral obstruction (UUO) model. In addition, we
studied the relationship between TGF-b and VEGF-C in
cultured proximal and collecting tubules, macrophages and
fibroblasts, which are involved in tubulo-interstitial fibrosis.
This is the first report to examine the mechanisms and roles
of TGF-b in lymphangiogenesis.
RESULTS
Basic characteristics of the rat UUO model
Three days after ligation, dilation of the tubules and infil-
tration of inflammatory cells were seen in both the cortex and
the medulla. On day 14, tubular degeneration, dilation, and
atrophy became severe and intense interstitial fibrosis was
also observed (Figure 1). Morphological analysis demon-
strated strong infiltration of CD68 (ED-1)-positive macrophages
in both the cortex and medulla on day 3 that was more
prominent than the expression of a-smooth muscle actin
(a-SMA)-positive fibroblasts (Figure 2a and b). Expres-
sion of a-SMA-positive fibroblasts and type III collagen
deposition in the tubulo-interstitial area became conspicuous
and peaked on day 14 (Figure 2).
Lymphatic vessels in control and UUO model
In the control kidney, podoplanin-positive and lym-
phatic endothelial hyaluronan receptor-1 (LYVE-1)-positive
lymphatic vessels were not encountered in the normal
cortical tubulo-interstitial area and were observed only
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Figure 1 |Rat unilateral ureteral obstruction (UUO) model. (a) Renal cortex of rat UUO model. (b) Renal medulla of rat UUO model.
Arrows, arrowheads, asterisks, triangles, and stars indicate the same dilated tubules. Bar¼ 100 mm. ED-1, CD68; P, renal pelvis; PAS, periodic
acid–Schiff; a-SMA, a-smooth muscle actin.
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adjacent to the large and intermediate-sized vessels (Figures
3a, b, and 4). In the glomeruli, podoplanin was expressed
in the podocytes and parietal epithelial cells. In contrast,
LYVE-1 was expressed in the glomerular endothelial cells
detected by anti-aminopeptidase P antibody, a marker of rat
endothelial cells,21 on serial sections and double staining
(Figure 3a–c, Supplementary Figure S1a–c online). In the
kidney with ureteral obstruction, podoplanin- and LYVE-1-
positive lymphatic vessels grew with time and peaked on day
14 in both the medullary and cortical areas (Figures 3d–g and
4). On serial sections of the medulla on day 14, a number of
podoplanin- and LYVE-1-positive lymphatic vessels that were
negative for aminopeptidase P were observed, and the entry
of the lymphatics was confirmed in the renal pelvis (red and
blue arrows in Figure 3h–j). On the other hand, endothelial
cells of the blood vessels were negative for podoplanin and
LYVE-1 (Figure 3h–j). The expression pattern of podoplanin
in the interstitial area was similar to that of LYVE-1 (Supple-
mentary Figure S1d–i). The expression pattern in the glomer-
uli of these three markers (Figure 3h–j) was the same as those
in control kidneys (Figure 3a–g).
Expression of VEGF-C and TGF-b, and lymphangiogenesis
during UUO
Because TGF-b is known to have an important role in
the pathogenesis of tubulo-interstitial fibrosis,22 expression
of TGF-b was compared with that of VEGF-C in this model.
On immunohistochemistry, expression of TGF-b protein
detected by anti-TGF-b 1, 2 and 3 antibodies was seen to
increase gradually, peaking on day 14 (Figure 4); this expres-
sion was primarily seen in the tubular epithelial cells, and was
partly seen in the inflammatory cells. TGF-b expression in
the glomeruli was not elevated. In the control kidney, VEGF-
C was weakly detected in the tubular epithelial cells (day 0,
Figure 4). VEGF-C expression was also gradually upregu-
lated, mainly in the enlarged tubular epithelial cells in both
the cortex and medulla after disease induction. Although
we were able to detect VEGF-C in the infiltrating cells in
the tubulo-interstitial area on days 9 and 14, expression
was more marked in the tubules than in the inflammatory
cells (Figure 4, Supplementary Figures S2–4 online). Morpho-
metric analysis demonstrated that TGF-b and VEGF-C
expression paralleled lymphangiogenesis (Figure 5).
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Figure 1 |Continued.
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Localization of VEGF-C and TGF-b protein in UUO (day 14)
To identify the segments of tubules that expressed VEGF-C
and TGF-b, serial sections were stained with aquaporin-1
and aquaporin-2. VEGF-C and TGF-b were expressed by
the aquaporin-1-positive proximal tubules and aquaporin-2-
positive collecting tubules in the injured tubulo-interstitial
areas of the cortex and the medulla (Figure 6). Interestingly,
localization of VEGF-C was similar, and often showed
co-localization with TGF-b (Figure 6, Supplementary
Figure S3 online).
VEGF-C, TGF-b, podoplanin, and LYVE-1 messenger RNA
(mRNA) expression analyzed by real-time polymerase
chain reaction (PCR) in UUO
All isoforms of TGF-b and VEGF-C mRNA increased with
time, and peaked on day 14 in both the cortex and medulla
(Figure 7a–d). mRNA expression of LYVE-1, podoplanin,
and vascular endothelial growth factor receptor-3, markers
of lymphangiogenesis, increased over time and peaked on
day 14 (Figure 7e–h, Supplementary Figure S5a and b online).
These kinetics were similar to those of TGF-b and VEGF-C
mRNA and protein (Figures 5a, b, and 7a–d). These expres-
sion patterns were also comparable to the expression of
a-SMA and type III collagen, but not ED-1-positive macro-
phages (Figure 2). These findings indicate that lymphangio-
genesis developed in association with the fibrotic process. In
contrast, the expression of VEGF-A mRNA, the most potent
mediator of neoangiogenesis, was slightly lower on day 3, but
was not significantly altered during the observation period
(Supplementary Figure S6 online).
VEGF-C induction by TGF-b1 in cultured proximal
tubular epithelial (HK-2) cells, collecting duct (M-1) cells,
macrophages (RAW264.7) and fibroblasts (NRK-49F)
To explore the roles of TGF-b in lymphangiogenesis, we
investigated VEGF-C induction by TGF-b1 in cultured
proximal tubular epithelial cells, collecting duct cells, macro-
phages and fibroblasts, which are involved in the develop-
ment of tubulo-interstitial injury of UUO (Figure 8).
In human kidney-2 (HK-2, human proximal tubular
epithelial cells), dose–response studies were conducted using
incubation for 24 h with recombinant TGF-b1 at 0, 1, 5,
or 20 ng/ml. TGF-b1 induced significant upregulation of
VEGF-C protein (Po0.001), determined by an enzyme-
linked immunosorbent assay and VEGF-C mRNA expression
(Po0.001), determined by real-time PCR (Figure 8a and c).
On the basis of these experiments, time-course studies
were performed using 5 ng/ml TGF-b1. VEGF-C mRNA/18S
ribosomal RNA increased by about a 2- to 2.5-fold and
peaked at 12 h. VEGF-C protein was secreted into super-
natants under serum-free conditions and without TGF-b
incubation. TGF-b1 significantly induced VEGF-C protein
secretion at 24 h (Po0.001, Figure 8b).
In the M-1 mouse cortical collecting duct cell line, TGF-b1
induced the upregulation of VEGF-C mRNA expression.
VEGF-C mRNA/18S ribosomal RNA increased and peaked
24 h after incubation with 5 ng/ml TGF-b1 (Figure 8e and f).
In mouse macrophages (RAW264.7), concentrations above
5 ng/ml TGF-b1 significantly increased VEGF-C mRNA
expression (Po0.05, Figure 8g). VEGF-C mRNA/18S ribo-
somal RNA was elevated and peaked at 12 h after incubation
with 5 ng/ml TGF-b1 (Figure 8h). VEGF-C induction by
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Figure 2 |Quantification of morphological analysis by
immunohistochemistry in rat unilateral ureteral obstruction.
CD68 (ED-1)-positive macrophage infiltration (a) increased
significantly on day 3 and continued to increase until day 14.
Areas positive for a-smooth muscle actin (a-SMA) (b) and type III
collagen (c) increased with time and peaked on day 14. Values are
means±s.e. (N¼ 5). *Po0.05; **Po0.005; #Po0.01; ##Po0.001 vs.
control.
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Figure 3 | Lymphatic vessels in normal and obstructed kidneys. (a–c) Immunohistochemical staining for podoplanin (a), lymphatic
endothelial hyaluronan receptor-1 (LYVE-1) (b) and aminopeptidase P (c) on serial sections of normal rat kidney. Podoplanin and
LYVE-1-positive lymphatic vessels were rarely detected in the normal architecture of the cortico-medullary tubulo-interstitial area.
Lymphatics (* and arrows) were observed adjacent to the intermediate-sized vessels (#). In the glomeruli, podoplanin was detected in
podocytes and parietal epithelial cells of Bowman’s capsule (a). LYVE-1 was also expressed in the glomeruli (b). Expression of
aminopeptidase P was observed in the peritubular capillaries and glomerular endothelial cells (c). Bar¼ 100mm. (d–g) Immunohistochemical
staining for podoplanin in the cortex of the unilateral ureteral obstruction (UUO) model. No lymphatic vessels were detected on day 0
(d). There were only a few lymphatic vessels in the cortex of the UUO model on day 3 (e). On day 9 (f) and day 14 (g), the number of
lymphatic vessels were increased in the tubulo-interstitial injured area. Bar¼ 200mm. (h–j) Lymphatic vessels and blood vessels in the renal
medulla in UUO on day 14. Immunohistochemical staining for podoplanin (h), LYVE-1 (i) and aminopeptidase P (j). Lymphatic vessels (*)
expressed LYVE-1 and podoplanin, but did not express aminopeptidase P. The entry of the lymphatics (red and blue arrows) was
confirmed in the renal pelvis (RP). Vein (#) was positive for aminopeptidase P, but negative for podoplanin and LYVE-1. Bar¼ 200 mm.
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Figure 4 | Expression of growth factors and lymphatic vessels in unilateral ureteral obstruction. Immunohistochemical staining for
transforming growth factor-b (TGF-b), vascular endothelial growth factor-C (VEGF-C), and lymphatic endothelial hyaluronan receptor-1
(LYVE-1) on serial frozen sections in the cortex (a) and in the medulla (b). TGF-b and VEGF-C were expressed in tubular epithelial cells
(arrows and arrowheads), and were upregulated with time after ureteral obstruction in both the medulla and cortex. LYVE-1-positive
lymphatic vessels were revealed and increased with time. Black and blue arrows and arrowheads indicate the same tubules. Bar¼ 200mm.
P, renal pelvis.
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TGF-b1 in these cells was suppressed by TGF-b type I receptor
inhibitor LY364947 (LY) in a dose-dependent manner
(Figure 9).
On the other hand, in the NRK-49F rat renal fibroblast cell
line, VEGF-C mRNA was not upregulated in dose–response
experiments (0, 1, 5 or 20 ng/ml) or by 5 ng/ml TGF-b1 at
any time points (data not shown).
Effects of TGF-b type I receptor inhibitor (LY364947) on
lymphangiogenesis in UUO
To investigate the effects of the TGF-b–VEGF-C pathway
on lymphangiogenesis in UUO, we administered LY364947
into the obstructed kidney via the aorta. LY364947
suppressed type III collagen, VEGF-C and LYVE-1 mRNA
expression resulting in a reduction in the number of
lymphatics (Figure 10).
DISCUSSION
Sustained injury by persistence of the initiating events,
such as immunologically mediated glomerulonephritis
and tubulo-interstitial nephritis, hemodynamic disorders,
and metabolic diseases, may lead to a chronic and fibrogenic
inflammatory response involving macrophage infiltration,
fibroblast proliferation and accumulation of extracellular
matrix.23–25 Inflammation is thought to have an important
role in lymphatic development in several disease condi-
tions, and macrophages have been suggested to stimulate
lymphangiogenesis by acting as a source of lymphatic
endothelial progenitor cells and by providing a crucial source
of pro-lymphangiogenic growth factors.10,11,13–15,17,18,26,27
In our recent reports on human renal diseases, we found
that lymphangiogenesis was affected by the duration of
inflammation and progression of fibrosis, rather than by acute
inflammation.20 Tubulo-interstitial fibrosis in a rat remnant
kidney model was also reported to be associated with newly
formed lymphatic vessels.21 In other organs, lymphatic
proliferation was confirmed in human idiopathic pulmonary
fibrosis and bleomycin-induced pulmonary fibrosis in rats.18,28
However, conflicting data between tissue fibrosis and lym-
phangiogenesis have recently been reported.29–31 TGF-b was
reported to directly inhibit growth of lymphatic endothelial
cells.29–31 In addition, TGF-b type I receptor inhibitor
enhanced their proliferation.29 To address the different aspects
of lymphatic proliferation in tubulo-interstitial fibrosis on the
human biopsy specimens,20 we investigated the roles of TGF-b
and VEGF-C on lymphangiogenesis in UUO. In our analysis of
a UUO model on day 3, numerous infiltrating macrophages
had already appeared, but only weak upregulation of VEGF-C
and slight lymphatic proliferation were confirmed (Figures 2,
5, and 7). From days 9 to 14 in rat UUO, we observed that
lymphangiogenesis was associated with tubulo-interstitial
fibrosis and chronic inflammation. In addition, VEGF-C
expression was elevated in both the cortex and medulla with
time after ureteral ligation, and paralleled TGF-b expression
(Figures 4, 5, and 7). These findings suggest that the fibrotic
process with chronic inflammation may be linked with
lymphangiogenesis rather than acute inflammation.
VEGF-C is known to be one of the most important medi-
ators of lymphangiogenesis.16,32 VEGF-C has been shown to
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Figure 5 |Quantification of morphological analysis of
transforming growth factor-b vascular endothelial growth
factor-C (VEGF-C), and lymphatic endothelial hyaluronan
receptor-1 (LYVE-1) expression in unilateral ureteral
obstruction (UUO) model. TGF-b (a) and VEGF-C (b) expression
increased with time. The number of LYVE-1-positive lymph vessels
(c) was counted in ten random areas in the medulla and cortex of
the UUO kidney. LYVE-1-positive lymphatics increased markedly in
the medulla on day 9 and day 14. Values are means±s.e. (N¼ 5).
*Po0.05; **Po0.005; #Po0.01; ##Po0.001 vs. control.
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Figure 6 | Localization of vascular endothelial growth factor-C (VEGF-C) and transforming growth factor-b (TGF-b) protein in
unilateral ureteral obstruction (UUO) (day 14). Immunohistochemical staining for VEGF-C, TGF-b, aquaporin-1, and aquaporin-2 in
the same rat UUO kidney on day 14. VEGF-C is expressed in the aquaporin-1-positive proximal tubules and in the aquaporin-2-positive
collecting ducts (arrows and *) in the injured tubulo-interstitial area. TGF-b is often co-localized with VEGF-C both in the cortex and
the medulla. (a–d) VEGF-C staining; (e, f) TGF-b staining; (g, h) aquaporin-1 staining; (i, j) aquaporin-2 staining. Left panel (a, c, e, g, i): cortex;
right panel (b, d, f, h, j): medulla. (c, d) Enlargement of the rectangular frame of a and b, respectively. Bar¼ 200 mm.
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be required for the normal development of lymphatic vessels,
particularly those sprouting from the embryonic veins.3 To
clarify the roles of TGF-b in lymphangiogenesis, we
investigated VEGF-C induction by TGF-b1 in cultured
proximal tubular epithelial cells (HK-2), collecting duct cells
(M-1), macrophages (RAW264.7), and fibroblasts (NRK-
49F) (Figure 8). We detected basal VEGF-C expression in all
cell lines. Notably, significant increases in VEGF-C expression
in response to TGF-b1 were seen in cultured proximal
tubular epithelial cells, collecting duct cells and macrophages,
but not in fibroblasts. In UUO, TGF-b expression increased
over time and was preferentially increased in tubular
epithelial cells and to a lesser degree in infiltrating macro-
phages (Figure 4, Supplementary Figures S2–4 online), which
is consistent with previous reports of precise studies by
in situ hybridization, competitive PCR and immunohisto-
chemistry.33,34 Tubular epithelial cell injury induced by UUO
may also affect TGF-b and VEGF-C expression. The strong
expression of VEGF-C in aquaporin-1- and -2-positive
tubular epithelial cells in vivo (Figure 6) and in culture
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Figure 7 |Quantitative analysis of transforming growth factor-b (TGF-b), vascular endothelial growth factor-C (VEGF-C), lymphatic
endothelial hyaluronan receptor-1 (LYVE-1) and podoplanin messenger RNA (mRNA) expression in unilateral ureteral obstruction
(UUO) model. Expression of mRNA was analyzed by real-time reverse transcription-polymerase chain reaction. TGF-b, VEGF-C, LYVE-1, and
podoplanin mRNA expression in both the medulla and cortex increased and peaked on day 14. (a, c, e, g) Medulla of UUO kidney; (b, d, f, h)
cortex of UUO kidney. (a, b) TGF-b mRNA; (c, d) VEGF-C mRNA; (e, f) LYVE-1 mRNA; (g, h) podoplanin mRNA. Values are means±s.e. (N¼ 5).
*Po0.05, **Po0.005, #Po0.01 vs. control.
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studies suggests that tubular epithelial cells are an important
source of VEGF-C in UUO (Figure 8). On reverse
transcription–PCR, we were not able to detect vascular
endothelial growth factor receptor-2 and -3 in cultured
proximal tubular epithelial cells, collecting duct cells, fibro-
blasts, and macrophages (Supplementary Figure S7 online),
which suggests that VEGF-C does not act in an autocrine
manner. Vascular endothelial growth factor receptor-3 was
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Figure 8 |Vascular endothelial growth factor-C (VEGF-C) expression in cultured proximal tubular epithelial cells (human kidney-2
(HK-2)), collecting duct cells (M-1) and macrophages (RAW 264.7) after treatment with transforming growth factor-b1 (TGF-b1).
(a–d) HK-2 proximal tubular epithelial cell line; (e, f) M-1 collecting duct cell line; (g, h) RAW 264.7 macrophage cell line. (a–d) HK-2 cells,
preincubated for 24 h in serum-free medium, were treated with TGF-b1. VEGF-C protein level in the supernatant was determined by
enzyme-linked immunosorbent assay (a, b), and VEGF mRNA level was determined by real-time reverse transcription-polymerase chain
reaction (c, d). 18s ribosomal RNA (rRNA) was used as an internal control. VEGF-C protein levels increased significantly in response to 1, 5,
and 20 ng/ml TGF-b1 at 24 h (a). VEGF-C mRNA expression was also elevated in response to 1, 5, and 20 ng/ml TGF-b1 at 24 h; it significantly
increased at 6 h and peaked at 12 h with 5 ng/ml TGF-b1 (c, d). (e, f) M-1 cells were treated with TGF-b1. VEGF-C mRNA expression was
significantly increased by stimulation with more than 1 ng/ml TGF-b1. (g, h) RAW264.7 cells were treated with TGF-b1. VEGF-C mRNA
expression was elevated in response to TGF-b1 stimulation. Data are means±s.e. (N¼ 3). *Po0.05, **Po0.005, ##Po0.001 vs. control.
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only detected in the lymphatics in vivo (Supplementary
Figure S5e–g online). These findings suggest that TGF-b1 is
the central inducer of VEGF-C leading to lymphangiogenesis
in tubulo-interstitial fibrosis of UUO. In the human chronic
glomerular diseases associated with tubulo-interstitial injury,
VEGF-C expression was also observed in the tubular
epithelial cells.20 Recent reports have indicated that TGF-b
directly inhibits lymphatic endothelial cell proliferation and
migration.29–31 In the cultured NRK-49F fibroblasts of our
study, VEGF-C induction by TGF-b1 was not significant,
despite the presence of basal expression (Figure 11). These
findings suggest that fibroblasts do not directly enhance
lymphangiogenesis. However, in the kidney, VEGF-C pro-
duction by tubular epithelial cells may have a crucial role in
the growth of lymphatics, in contrast to the situation in other
organs. In the process of lymphatic growth, the effects of
VEGF-C produced by these cells may exceed the direct effects
by TGF-b on the lymphatic endothelial cells, and the balance
between these two factors may control the extent of
lymphangiogenesis. The limitation in in vivo experiments is
the difficulty of systemic administration of TGF-b receptor I
inhibitor in UUO. Low doses (1 mg/body g/day intraperito-
neally) of LY364947 did not reduce the collagen expression,
and rats cannot tolerate high doses (3 mg/body g/day
intravenously). Therefore, we administered LY364947 to
obstructed kidney via the aorta, which resulted in inhibition
of TGF-b, VEGF-C and LYVE-1 (Figure 10). Although it
remains unclear whether fibrosis with collagen deposition
can modulate lymphangiogenesis, at least TGF-b upregulated
VEGF-C in renal cells leading to lymphangiogenesis in UUO.
Thus, our data indicate that TGF-b is a critical regulator
of VEGF-C, and lymphatic proliferation is likely to depend
on the TGF-b–VEGF-C pathway in UUO (Figure 11).
Conversely, VEGF-A mRNA expression was not significantly
affected (Supplementary Figure S5 online), which is consis-
tent with previous reports. In contrast to the proliferation of
lymphatics, peritubular capillary density was shown to
decrease in areas of tubulo-interstitial scarring.35
In our studies, we used three markers to discriminate
between lymphatics and blood vessels. Podoplanin, a
transmembrane glycoprotein, is expressed by lymphatic
endothelial cells, but not by blood endothelial cells.10,11
However, it has been reported that podoplanin is expressed in
keratinocytes, type I epithelial cells of the lung, mesothelial
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cells, myoepithelial cells, and glomerular podocytes.21,26
LYVE-1 was first identified as a CD44 homolog and is used
as a specific marker of lymphatic endothelial cells.26,36–38
LYVE-1 is also known to be expressed by liver sinusoids with
fenestration, pulmonary capillaries, and some macro-
phages.26,39 We found that glomerular endothelial cells,
which have a fenestration structure, are extra sites that
express LYVE-1 (Figure 3). This was confirmed by double
staining with aminopeptidase P, which is a specific marker of
endothelial cells in rat blood vessels (Figure 3).21 In this
respect, both markers have limitations as specific markers for
lymphatic endothelial cells. We successfully identified the
entry of the lymphatic vessels, which were positive for podo-
planin and LYVE-1, and negative for aminopeptidase P, into
the renal pelvis (Figure 3h–j). A previous study revealed that
obstruction of the ureter resulted in a marked increase
in thoracic duct lymph flow and pressure in UUO.40 In addi-
tion, lymphatic ligation leads to an increase in renal intersti-
tial pressure.41,42 In a clinical case of chyluria due to filariasis,
occlusion of the thoracic duct was demonstrated by pedal
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lymphangiography (Supplementary Figure S8a). Enhance-
ment with contrast media on a computed tomography scan
of the renal pelvis strongly suggested an interconnection
between lymphatics and the urinary excretion system in
chyluria (Supplementary Figure S8c online). These findings
indicate that there is a connection between pelvic and
systemic lymphatic circulation, which may reduce pelvic
pressure.
In summary, we demonstrated that lymphatic vessels
proliferate and show a correlation with TGF-b expression in
UUO. Thus, TGF-b has an important role in the progression
of lymphangiogenesis. Tubular epithelial cells and macro-
phages are involved in the progression of lymphangiogenesis
in UUO, and the TGF-b–VEGF-C pathway might have a
crucial role. Knowledge regarding the effects of TGF-b
on VEGF-C in renal cells may enhance our understanding of
the underlying mechanisms and may lead to strategies for
modulating lymphatics in chronic renal diseases. Stimulation
of lymphatic growth was recently considered as a new target in
some disease states. The relative importance of lymphangio-
genesis will have to be established by manipulation of VEGF-C
levels in chronic renal injury models in the future.
MATERIALS AND METHODS
Animals and experimental design
All animal studies were carried out in accordance with the animal
experimentation guidelines of Nagoya University Graduate School
of Medicine (Nagoya, Japan). Seven-week-old male Sprague-Dawley
rats (Japan SLC, Hamamatsu, Japan) initially weighing 210–230 g
were used. After induction of anesthesia, the left flank was opened
through a small incision and the left ureter was completely ligated
with 2-0 suture at two points and cut between the ligatures to
prevent retrograde infection. Rats were killed on days 0, 3, 9, and 14
after UUO (n¼ 5 for each time point), and both the obstructed
kidney and contralateral kidney were collected. To investigate the
TGF-b–VEGF-C pathway on lymphangiogenesis in UUO, we admin-
istered TGF-b type I receptor inhibitor LY364947 (2 mg/body g in
saline; Calbiochem, La Jolla, CA) or saline alone into the obstructed
kidney via the aorta with a 28-gauge needle while clamping the aorta
just above the left renal artery on 3 consectutive days from days 2
to 4. Rats were killed and evaluated on day 5. The left kidney was
processed for routine histology, immunohistochemistry, and total
RNA isolation. Kidney specimens were cut into transverse
fragments. One part was fixed for 16 h in 10% buffered formalin
and embedded in paraffin by conventional techniques. Sections were
stained with periodic acid–Schiff ’s stain and Masson’s trichrome.
Formalin-fixed tissue was also used for immunohistochemistry as
detailed below. A second part was snap-frozen in liquid nitrogen.
Sections (4mm) were cut with a cryostat and used for immuno-
histochemistry. A third part of the excised left kidney was cut and
divided into the cortex and medulla, which were immersed in
RNAlater (Ambion, Austin, TX) for total RNA isolation. To preserve
the integrity and stability of total RNA, all steps were performed at
4 1C under sterile conditions.
Histology and immunohistochemistry
Immunostaining for type III collagen, a-SMA, monocytes/macro-
phages (ED-1), podoplanin, LYVE-1 and aminopeptidase P was
performed on buffered formalin-fixed tissues, and for VEGF-C,
TGF-b, and LYVE-1 staining, immunostaining was performed using
4-mm cryostat sections, as described previously (Supplementary
Table S1 online).20,24,43
Morphological analysis
To assess the relationship between lymphangiogenesis and tubulo-
interstitial injury, morphological analysis was separately performed
in both the cortex and medulla. Tubulo-interstitial injury was
assessed by inflammation (ED-1-positive cells) and by fibrotic
processes (a-SMA-positive cells and type III collagen). ED-1-
positive macrophages and LYVE-1-positive lymphatic vessels were
identified and counted in the cortex and medulla using Zeiss Z1
image microscopy and Axiovision Windows software version 4.4
(Carl Zeiss, Oberkochen, Germany). These were counted in 10
random 750 500-mm areas of both the cortex and the medulla
at  200 magnification, and are expressed in terms of counts
per square millimeter. Areas positive for a-SMA, type III collagen,
TGF-b 1, 2, and 3, and VEGF-C were assessed in 10 random high-
powered fields ( 200) of both the cortex and the medulla using
MetaMorph 6.3 image analysis software (Universal Imaging, West
Chester, PA).
Cell culture study
Human HK-2 proximal tubular cell lines were purchased from the
American Type Culture Collection (ATCC, Manassas, VA) and were
TGF-  1
Fibroblasts
Macrophages Collecting
duct cells
VEGF-C
production
Promote
Basal expression
Lymphangiogenesis
Proximal
tubular
cells
Figure 11 |Possible mechanisms of lymphangiogenesis via the
transforming growth factor-b (TGF-b)–vascular endothelial
growth factor-C (VEGF-C) pathway in unilateral ureteral
obstruction (UUO). TGF-b expression is upregulated in the
process of tubulo-interstitial fibrosis in UUO. TGF-b1 expressed by
tubular epithelial cells and macrophages induces the upregulation
of VEGF-C in proximal tubular epithelial cells (human kidney-2),
collecting duct cells (M-1), and macrophages (RAW264.7), leading
to lymphangiogenesis. In renal fibroblasts (NRK-49F), VEGF-C was
not elevated by TGF-b1, despite basal secretion into the
supernatant.
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maintained in medium containing Dulbecco’s modified Eagle’s
medium and Ham’s F-12 medium (Sigma, Tokyo, Japan) supple-
mented with 10% fetal bovine serum (FBS; Hyclone, Yokohama,
Japan).44 M-1 cells derived from the mouse cortical collecting duct
were purchased from the European Collection of Cell Cultures
(ECACC, No. 95092201; Salisbury, UK) and were grown in medium
containing a 1:1 mixture of Ham’s F-12 medium, Dulbecco’s
modified Eagle’s medium, 5 mmol/l dexamethasone and 5% FBS.
RAW 264.7 cells derived from murine macrophages were purchased
from ATCC, and were cultured in Dulbecco’s modified Eagle’s
Medium (Sigma) containing 10% FBS. A rat renal fibroblast cell line
(NRK-49F) was purchased from ATCC, and was grown in medium
containing Dulbecco’s modified Eagle’s medium supplemented
with 5% FBS. All cells were cultured in humidified air with 5%
CO2 at 37 1C. All experiments were performed between passages two
and six.
All cells were plated at a density of 2 105 cells in 6-cm dishes
and grown. Under subconfluent conditions, cells were washed twice
with phosphate-buffered saline, and culture medium was replaced
with serum-free medium for 24 h to render cells quiescent.
Subsequently, cultures were incubated with 5 ng/ml recombinant
human TGF-b1 (R&D System, Minneapolis, MN) diluted in serum-
free medium. Cells were collected at 0, 6, 12, and 24 h after incu-
bation, and all conditioned media were collected for enzyme-linked
immunosorbent assay. For determination of dose response to
TGF-b1 stimulation, cells were cultured for 24 h in media
supplemented with 0, 1, 5, or 20 ng/ml TGF-b1 after starvation
for 24 h. In inhibition studies, cells were incubated with 5 ng/ml
TGF-b1 in combination with a selective inhibitor of TGF-b receptor
I (LY364947) for 24 h.
Total RNA isolation from rat kidney tissues and cultures cells
Total RNA was extracted from rat kidney tissues and cultured cells
using the RNeasy Mini Kit (Qiagen, Hilden, Germany). Total
RNA concentrations were estimated using a spectrophotometer
(Ultrospec 3300 pro; Amersham Biosciences, Tokyo, Japan). Rat
kidney tissues were immersed in RNAlater (Ambion, Austin, TX)
for 1 day. The mixture was ground for 2min with 5-mm tungsten
carbide beads at a frequency of 27 Hz using a mixer-mill
grinder according to the manufacturer’s instructions (Tissuelyser;
Qiagen).
Polymerase chain reaction
For both animal samples and cultured cells, first-strand cDNA was
synthesized using the QuantiTect Reverse Transcription Kit (Qiagen)
for animal samples or High Capacity Reverse Transcription Kit
(Applied Biosystems, Foster City, CA) for cultured cells, according to
the manufacturers’ instructions. Total RNA (1mg) was then reverse
transcribed. Real-time PCR analysis was performed with an
Applied Biosystems Prism 7500HT sequence detection system using
TaqMan gene expression assays, as described previously.45 TaqMan
gene expression assays (Applied Biosystems) were used (Supplemen-
tary Table S2 online). 18S ribosomal RNA was used as an endogenous
control.
VEGF-C enzyme-linked immunosorbent assay
Secretion of VEGF-C into culture supernatants was determined
using the Human VEGF-C Assay kit (IBL, Takasaki, Japan),
according to the manufacturer’s instructions.
Statistical analysis
Values are expressed as means±s.e. Comparisons among groups
were performed by one-way analysis of variance followed by
Dunnett’s or Tukey’s HSD (honestly significant difference) multiple
comparison test. Comparisons between LY364947 and saline
groups in in vivo experiments were assessed by Mann–Whitney
U-test. Differences were considered to be statistically significant
at Po0.05. All analyses were performed using SPSS software
(SPSS, Chicago, IL).
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